Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. - Wikidata - wikimedia - TriplyDB

Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.

Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.

http://www.wikidata.org/entity/Q34083354

about

Update on inflammatory bowel disease in patients with primary sclerosing cholangitis Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1 A review of the medical treatment of primary sclerosing cholangitis in the 21st century Combination antiretroviral studies for patients with primary biliary cirrhosis Diagnosis and management of the overlap syndromes of autoimmune hepatitis High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice Recent advances in the development of farnesoid X receptor agonists Current research on the treatment of primary sclerosing cholangitis.The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II.A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis.The features of mucosa-associated microbiota in primary sclerosing cholangitis Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.The reversed feto-maternal bile acid gradient in intrahepatic cholestasis of pregnancy is corrected by ursodeoxycholic acid Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis.Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.Evolving concepts in primary sclerosing cholangitis.Recent insights in primary sclerosing cholangitis.The overlap syndromes of autoimmune hepatitis.Autoimmune hepatitis in diverse ethnic populations and geographical regions.Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis.Primary biliary cirrhosis: safety and benefits of established and emerging therapies.Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis.Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells.Effect of various antibiotics on modulation of intestinal microbiota and bile acid profile in mice Specific bile acids inhibit hepatic fatty acid uptake in mice.Defective canalicular transport and toxicity of dietary ursodeoxycholic acid in the abcb11-/- mouse: transport and gene expression studies.Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.Ursodeoxycholate modulates bile flow and bile salt pool independently from the cystic fibrosis transmembrane regulator (Cftr) in mice.Clinical trials and their translation in hepatology: past, present, and future.Dietary Bile Salt Types Influence the Composition of Biliary Bile Acids and Gut Microbiota in Grass Carp

P2860

Q24567496-0CF0724E-61DE-4111-AFD3-ACDB42B10536 Q26768128-0C295C49-E2C6-4B25-8232-29C568E2DFCA Q26771816-A5031B2F-3B95-4033-8E7A-9FAAA7DD7990 Q26772310-D63AEE2A-C008-4FA1-BDFE-F9ECEBCAF55E Q27003179-1AB2C489-C3A1-47CC-9FD7-7D82699A48DC Q28237152-469D4552-D6BE-4A0A-8286-B8929DED3EF8 Q33754301-5D2A9F4F-9AEC-4357-BE79-F078ADFF9F3D Q34464043-D56BA408-AA83-4DD0-834F-B7B20FEF80EA Q35066561-082BA6B9-B371-4E44-B155-08A259485A8F Q35535485-CE52E3DB-0F72-4B96-90C5-58DDDCEB666C Q35778052-A7753B43-4451-4ED1-8219-0574A9E42BFB Q35917819-737AD874-8085-4B2E-BB1D-45F4FEC66225 Q36197335-6B9FE274-292A-445B-8CAD-743E19F7375C Q37117971-86A025B4-E186-47B7-A457-847FC65E7AE2 Q37452047-C82CB9AA-26B4-4795-914C-886851F1763A Q37866339-04436FA9-8BD1-432E-9E9D-985A6465484A Q37919924-7FD641D5-BAA8-451E-B5AF-E4C82F04A835 Q37957967-CA66AB67-D964-408F-A0EA-A07A10CAD3A1 Q38019989-BD61C262-FE3A-49F2-A93D-F439802603A5 Q38037392-F7BDD09A-1816-4BB3-9B84-F80EDCA34D62 Q38103631-EFEBA1EE-04FF-427F-8F88-39D2591B437A Q38125078-95752C9A-A7F9-4141-87F5-95ACF1138F41 Q38554677-0039509D-B248-430E-8EBF-A5A788BC081B Q38833243-5B642CB7-AE87-46F8-A385-611B6A661535 Q39170726-B23DF7A1-4AC6-4DFE-AF8D-ECCBF9D89658 Q41166877-1AB1F8D4-9E51-4D51-BFEC-175B10EAFA56 Q42326059-4C6631D6-9A02-4A38-B249-72FA5239035E Q44511582-388C4D06-AEA0-47F4-BE55-8F46FC10CB5B Q46933007-685ABF4D-9883-4FAA-8AFA-109FD78A2D49 Q48190174-C4F990C0-286F-4B63-98CA-AE33343897E8 Q51643325-D3AA735F-F087-4BB3-9520-8F4D4925B3E2 Q57073739-7C95514F-1795-4621-9148-796B99CFC2EB

P2860

Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.

http://www.wikidata.org/entity/Q34083354

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Bile acid changes after high-d ...... lation to disease progression.

@ast

Bile acid changes after high-d ...... lation to disease progression.

@en

Bile acid changes after high-d ...... lation to disease progression.

@nl

type

label

Bile acid changes after high-d ...... lation to disease progression.

@ast

Bile acid changes after high-d ...... lation to disease progression.

@en

Bile acid changes after high-d ...... lation to disease progression.

@nl

prefLabel

Bile acid changes after high-d ...... lation to disease progression.

@ast

Bile acid changes after high-d ...... lation to disease progression.

@en

Bile acid changes after high-d ...... lation to disease progression.

@nl

P1433

Q34083354-991DA9CD-74DA-4FC3-8B8F-A182518CD355

P1476

Q34083354-FBE2A516-1A20-4AEE-83A6-DAD2EB57B1E3

P2093

Q34083354-1585398A-2BDB-40FC-B144-1D652AB556A7

Q34083354-2E8F041B-FDA6-40F3-A5A2-5CBA625E05D0

Q34083354-4338BAD0-AC08-41FE-965A-A3EEDF480F07

Q34083354-5FDB3215-15D3-4C81-B209-31E818CC86C1

Q34083354-8CFD2C3E-97B8-4C58-B6BC-3D706F6992DF

Q34083354-FF68F568-97B4-44DF-9E94-A7184B1B5B1A

P2860

Q34083354-173487DD-B812-470D-A939-04497262CF27

Q34083354-20C6E4FF-12DA-4FA0-ABEE-5A9AB7B035CB

Q34083354-2B1D35D6-89B1-42C3-BBD2-19D9C98F7197

Q34083354-2D18C43A-398A-4D3B-878A-38E877C370B8

Q34083354-3BE018B9-E9DB-4BB8-9541-58F5A7C87528

Q34083354-4D313DFF-315C-4874-A8A7-DDE62F597917

Q34083354-56CB259B-0404-40FB-A0ED-70C9BEA781CC

Q34083354-56F0AA9E-F402-4405-A6AD-B1ACD4B7F01C

Q34083354-5734F242-7762-42C3-AABD-D592B260AFE5

Q34083354-66C5BC07-2077-44C3-8688-19B3445288F6

P304

Q34083354-0B38778F-4B4D-42C4-A845-A0253036FC30

P31

Q34083354-BF6E89E2-2E5D-42A2-A250-66F4563EF2A2

P356

Q34083354-5DE14864-836C-4FB1-BCDC-21AD0B8266FD

P407

Q34083354-31E5EF12-E96C-4177-9BC7-99541ED6F4D0

P433

Q34083354-77398F5C-FB62-4ECF-AAB3-90907F5F919F

P478

Q34083354-F3DD542A-89EB-4DBA-A99F-DA9AAC3EB664

P577

Q34083354-4ECC06B5-DF2E-4F0E-9E5F-76030CFD0E4B

P5875

Q34083354-17CAFB1E-3083-4AEA-8470-5E52A35FEAF8

P698

Q34083354-AAEF610C-2B3F-4A42-8157-F8AE7C4CC977

P921

Q34083354-43194046-378C-475D-83D1-937536DE3391

P932

Q34083354-06C9E90A-70D5-44F9-8E37-F02F73B0F979

P356

P1433

P1476

Bile acid changes after high-d ...... lation to disease progression.

@en

P2093

Alex Befeler

http://www.w3.org/2001/XMLSchema#string

Emmanouil Sinakos

http://www.w3.org/2001/XMLSchema#string

Hanns-Ulrich Marschall

http://www.w3.org/2001/XMLSchema#string

Jill Keach

http://www.w3.org/2001/XMLSchema#string

Keith Lindor

http://www.w3.org/2001/XMLSchema#string

Kris V Kowdley

http://www.w3.org/2001/XMLSchema#string

P2860

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

Transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal bacteria

Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration

Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.

Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.

Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice.

Clinical features and management of primary sclerosing cholangitis.

A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation

Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid.

Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II.

P304

197-203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.23631

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44688941

http://www.w3.org/2001/XMLSchema#string

P698

20564380

http://www.w3.org/2001/XMLSchema#string

P921

P932

2928060

http://www.w3.org/2001/XMLSchema#string